Posted by paymon on Apr 22nd, 2016
Novo Nordisk A/S logoBbva Compass Bancshares Inc. raised its stake in Novo Nordisk A/S (NYSE:NVO) by 7.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 110,293 shares of the company’s stock after buying an additional 7,817 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Novo Nordisk A/S were worth $6,405,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of NVO. Park National acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $231,000. Janus Capital Management increased its stake in shares of Novo Nordisk A/S by 41.2% in the third quarter. Janus Capital Management now owns 275,847 shares of the company’s stock valued at $14,962,000 after buying an additional 80,515 shares in the last quarter. Stock Yards Bank & Trust Company increased its stake in shares of Novo Nordisk A/S by 0.4% in the fourth quarter. Stock Yards Bank & Trust Company now owns 283,266 shares of the company’s stock valued at $16,452,000 after buying an additional 1,067 shares in the last quarter. Assetmark increased its stake in shares of Novo Nordisk A/S by 252.5% in the third quarter. Assetmark now owns 79,386 shares of the company’s stock valued at $4,306,000 after buying an additional 56,864 shares in the last quarter. Finally, Beacon Capital Management acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $0.
Shares of Novo Nordisk A/S (NYSE:NVO) opened at 56.83 on Friday. The firm has a market cap of $144.79 billion and a P/E ratio of 27.76. Novo Nordisk A/S has a 12-month low of $46.17 and a 12-month high of $60.34. The company’s 50 day moving average price is $55.61 and its 200-day moving average price is $54.66.
The firm also recently announced an annual dividend, which was paid on Wednesday, March 30th. Stockholders of record on Tuesday, March 22nd were given a dividend of $0.704 per share. The ex-dividend date was Friday, March 18th.
Several equities research analysts have weighed in on NVO shares. Zacks Investment Research downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Monday, January 4th. Vetr raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating and set a $64.00 price target for the company in a report on Thursday, January 7th. Oddo Securities raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, January 26th. Goldman Sachs raised Novo Nordisk A/S from a “buy” rating to a “conviction-buy” rating in a report on Monday, February 15th. Finally, Citigroup Inc. reissued a “buy” rating on shares of Novo Nordisk A/S in a report on Friday, April 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $60.67.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals.
12 Month Chart for NYSE:NVO
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
Your Email Address
Sign-Up Now (Free)
«